AstraZeneca results: FY and Q4 2025

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Harmonised listing structure across NYSE, London, and Stockholm exchanges enables more shareholders to participate in the company's exciting future

  80% confidence

• Core EPS is expected to increase by a low double-digit percentage for FY 2026 at CER

  80% confidence

• In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.

  80% confidence

• Core Tax rate is expected to be between 18-22% for FY 2026

  80% confidence

• The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing.

  80% confidence

• Total Revenue is expected to increase by a mid-to-high single-digit percentage for FY 2026 at CER

  80% confidence

• Transformative technologies including substantial and growing number of trials have the potential to revolutionise outcomes for patients and drive growth well beyond 2030

  80% confidence

Data points we hold from this source